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Background: Significant progress has been made in understanding the molecular biology of ovarian
carcinoma. Along with the molecular characteristics of cancer, the patient’s response to the tumour
may also contribute to survival; in particular, the effect of the immune system may play an import-
ant role on survival of cancer patients.
Patients and methods: We analysed the CD3 positive tumour-infiltrating T cells and direct molecu-
lar assessment of T cell receptors (TCRs) gamma and beta in 95 advanced ovarian carcinomas.
Results: Gamma/delta T cells are statistically correlated with a brief disease-free interval
(P = 0.036). CD3 positive tumour-infiltrating T cells are correlated with a brief disease-free interval
and with survival (P = 0.004 and P = 0.0001, respectively). CD3 positive tumour-infiltrating T cells
are associated with clinical responsiveness to chemotherapy (P = 0.003).
Conclusions: Further studies are required to better understand the role of gamma/delta T cells in
ovarian carcinoma, yet these data underline the importance of host immune response to cancer and
the need to better study immune mechanisms to modulate the therapeutic treatment of cancer.
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Introduction
Among the gynaecologic malignancies, ovarian cancer is the
most common cause of death in Europe and North America.
Approximately 90% of all patients with ovarian carcinoma
underwent surgery followed by chemotherapy. Ovarian cancer
is a chemosensitive tumour, and platinum-based chemotherapy
can produce objective remissions in several cases. Neverthe-
less, a considerable diversity in behaviour may be found
among cases with similar clinical and pathological character-
istics, with some patients experiencing exceptionally long
survivals.
In recent years, significant progress has been made in
understanding the molecular biology of ovarian carcinoma and
in determining the importance that oncogenes and tumour
suppressor genes play in carcinogenesis and tumoural
progression.
Along with the molecular characteristics of cancer, the
patient’s response to the tumour may also contribute to shorter
or longer survival; in particular the effect of the immune sys-
tem on tumour development and progression may play an
important role in overall survival of cancer patients. Immunol-
ogists have hypothesised the possibility that the immune sys-
tem may eliminate cancers at an early stage and may permit
the progression of other tumours. An observation that supports
this hypothesis is that patients treated with immunosuppres-
sive drugs have an increased prevalence of malignances
compared with the control population [1].
There is some experimental evidence that the immune sys-
tem may also be involved in ovarian tumour progression, and
consequently in clinical outcome of ovarian cancer patients. In
fact, a lymphocytic infiltrate has been described in ovarian
carcinoma [2, 3], and recently, Zhang et al. [4] showed that
the presence of tumour-infiltrating T lymphocytes have a posi-
tive role in overall survival of ovarian carcinoma patients. The
presence of infiltrating tumour T lymphocytes correlated with
a better prognosis has also been reported for other tumours
such as breast, prostate, renal cell, colorectal and hepatocellu-
lar carcinoma, and also melanoma [5–10].
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T lymphocytes carry antigen-recognition molecules, the T
cell receptors (TCRs) gamma/delta or alpha/beta, on the cell
surface [11]. The gamma/delta T cells and the alpha/beta
T cells are commonly viewed as very different, in fact,
alpha/beta T cell-deficient mice show defective immunity
toward most pathogens [12], whereas gamma/delta T cell-
deficient mice show increased susceptibility to solid tumours
[13].
In the present study, we analysed the molecular assessment
of TCRgamma and TCRbeta of ovarian tumour-infiltrating T
lymphocytes and the CD3 positive ovarian cancer infiltrating
T cells. We investigated whether there was an association
between the presence of CD3 positive T cells and the presence
of gamma/delta T cells or alpha/beta T cells and clinical out-




We selected tissue blocks of serous ovarian carcinoma, FIGO (Inter-
national Federation of Gynecology and Obstetrics) stage III in the files of
the Department of Human Pathology and Oncology of the University of
Florence. The specimens were obtained from 95 patients with known fol-
low-up, all of whom underwent surgical and chemotherapeutic treatment
at the Department of Gynecology, Perinatology and Reproductive Medi-
cine of the University of Florence from 1985 to 1999. Informed consent
was obtained from all patients prior to surgery, and tumour samples were
collected during surgery. We have compared a group of patients living
with no evident disease 3 years after primary surgical treatment to a series
of patients who died of progression of disease within 3 years of primary
surgical treatment.
The women underwent a laparotomy for debulking of the gross neoplas-
tic masses with abdominal hysterectomy, bilateral salpingo-oophorectomy,
appendectomy and omentectomy with examination of the serosal surface
and biopsies of any suspected lesions.
All patients were staged retrospectively, according to a modified FIGO
staging system for malignant surface epithelial-stromal tumours [14].
A postoperative treatment was performed independently of the
presence of residual disease in all patients, consisting of combined che-
motherapy regimes with six cycles of cisplatin-based chemotherapy,
unless the patients showed disease progression during this adjuvant
treatment.
After completion of treatment, follow-up consisted of: a pelvic examin-
ation, measurement of tumour markers (CA-125, CEA, CA-19.9), pelvic
and abdominal ultrasonography (every 3 months for 2 years, and sub-
sequently every 6 months) and computer tomography (CT) of pelvis and
abdomen (annually). The follow-up period for each patient was until death
or at least 5 years after surgery.
The brief disease-free interval was defined as recurrence and/or metas-
tasis occurring within 12 months of surgery and primary chemotherapeutic
treatment [15, 16]. Patients with recurrent disease within 1 year of surgery
have a very poor prognosis.
We evaluated the clinical response to first-line chemotherapy treatment
according to CT of the pelvis and the abdomen with WHO (World Health
Organisation) methods [17]: complete response (CR), partial response
(PR), stable disease (S) and progression (P).
We analysed the following clinical, histopathological and immunohisto-
chemical variables: the age of the patients, the residual disease after sur-
gery assigned as 1 or 2 respectively, with absent/minimal residual disease
(<2 cm) or bulk residual disease (>2 cm) on completion of initial surgery
prior to chemotherapy, and the grade of differentiation (G1, G2, G3).
Moreover, the presence versus the absence of CD3 positive intratumoural
T cells, and the presence versus the absence of gamma/delta T cells and
alpha/beta T cells in ovarian carcinoma were also measured.
Tissue specimens and immunohistochemistry
The specimens were obtained by surgical resection in all cases and fixed
in 10% formalin before being processed in paraffin. Hematoxylin–eosin
stained sections from each histological specimen were reviewed by two
pathologists to confirm the histological diagnosis and to select one repre-
sentative paraffin block from each case for further studies. For immuno-
histochemical analysis, 3mm sections were prepared, each section was
deparaffinized using xylene and subsequently hydrated. The immunohisto-
chemical studies were performed by the streptavidin–biotin–peroxidase
method (UltraVision kit, LAB VISION, Fremont, CA) with diaminobenzi-
dine as chromogen and hematoxylin as nuclear counterstain. As primary
antibody we used a commercial mouse monoclonal confirme anti-CD3
(clone PS1) antibody (Ventana Medical Systems, Tucson, AZ) directed
against an epitope present on T cells. All tissue sections then were placed
on the Ventana automated stainer BenchMark XTe ICH system using as
rivelation system iVIEW DAB Detection Kit. Primary antibody anti-CD3
was placed on the tissue sections and incubated for 32 min at 378C. A
negative control sample was included with each run by omitting the pri-
mary antibody and yielded no signal. Sections of positive CD3 tonsilla
were used as positive control tissue. The control sections were treated in
parallel with the samples in the same run. The immunohistochemically
stained sections were evaluated without previous knowledge of the clinical
outcome of each patient.
Evaluation of immunohistochemical staining
T cells were counted manually in 20 high-power fields. Intratumoural T
cells were graded as 1+, 2+ and 3+ (5, 6–19 or 20 T cells per high-power
field, respectively), as previously described [4]. To assess the interobser-
ver variability in the evaluation of immunohistochemical staining, the
evaluations of one author were compared with those of one of the other
authors. Initially the slides were evaluated independently, and those
graded diversely were subsequently reevaluated by the two authors
together under a discussion microscope. The immunohistochemical analy-
sis was evaluated in a blinded fashion with regard to the clinical data.
DNA extraction and genetic analysis of TCRgamma
and TCRbeta
DNA was isolated from formalin-fixed, paraffin-embedded tissue sections.
After dewaxing and proteinase K digestion, the DNA was heated to 968C
for 10 min to destroy proteinase K activity.
The PCR assay for TCRgamma rearrangement was performed in
accordance with the previously described method [18], with slight
modifications. In brief, the consensus primers were TVgamma (50-AGGG-
TTGTGTTGGAATCAGG-30) and TJgamma (50-CGTCGACAACAAGT-
GTTGTTCCAC-30).
The assay is a two-step PCR. The first reactions were carried out in a
volume of 20ml, with 1.5 mM MgCl2, 0.125 mM dNTPs, 2 pmol of
TJgamma primer and 1 U Taq polymerase (Applied Biosystems, USA)
with 200–350 ng of DNA template. The cycle conditions were: 15 s at
948C, 20 s at 588C and 20 s at 728C for 25 cycles.
Later on, 20ml of fresh PCR reagents were added to the products of the
first amplification, at concentration of 1.5 mM MgCl2, 0.375 mM dNTPs,
12 pmol of TJgamma primer, 18 pmol of TVgamma primer and 1 U Taq
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polymerase. The cycles of this second amplification were 31 with the
same parameters as the previous reaction.
The PCR for TCRbeta rearrangement was performed in accordance
with the previously described method [19]. The primers were D2
(50-TCATGGTGTAACATTGTGGGGAC-30) and J2 (50-AGCACBGTGA-
GCCKGGTGCC-30). The reactions were carried out in a volume of 50ml,
with 1 mM MgCl2, 0.25 mM dNTPs, 25 pmol of each primer and 1 U Taq
polymerase. The cycle conditions were: 30 s at 948C, 45 s at 648C and 45 s
at 728C for 34 cycles.
PCR products were analysed by 15% acrylamide gel electrophoresis
and visualised under UV illumination after ethidium bromide staining. In
this way, a broad smear can be obtained from a sample with infiltration of
polyclonal reactive T cells. Instead a discrete band suggests the presence
of a monoclonal T lymphocyte proliferation. A PCR not showing smears
or bands after polyacrylamide gel electrophoresis means a tissue does not
contain reactive T cells.
Statistical analyses
The presence of CD3 positive intratumoural T cells and of the gamma/
delta T cells, in the two groups of ovarian carcinoma patients, in relation
to the brief disease-free interval, to the survival and to the clinical respon-
siveness to first line chemotherapy, was calculated according to logistic
regression in univariate and multivariate analyses [20]. The shift in
location of months of disease-free interval and of survival according to
the presence or absence of CD3 positive intratumoural T cells was calcu-
lated according to the Wilcoxon Mann–Whitney test [21]. The shift in
location of years of age in the ovarian carcinoma patients according to the
presence or absence of CD3 positive intratumoural T cells was calculated
according to the Wilcoxon Mann–Whitney test. Data analysis was per-
formed using the SPSS Version 11.0 (Chicago, IL) statistical package. A
P value <0.05 was considered to be statistically significant.
Results
In total 95 patients with advanced ovarian serous carcinoma
were included in the analysis. We compared 40 patients living
with no evident disease 3 years after primary surgical treat-
ment to 55 patients who died of progression of disease no
later than 3 years after primary surgical treatment. The ages of
living patients ranged from 40 to 74 years (mean age was 57.6
years and the average was 60 years). Concerning the grade of
differentiation, the series of living women was composed of
five ovarian serous carcinoma high grade of differentiation
(G1), 16 cases of G2, and 19 ovarian serous carcinoma low
grade of differentiation (G3). Concerning the residual disease
after surgery, 29 women (72.5%) had absent/minimal residual
disease after surgery (<2 cm) and 11 (27.5%) had bulk residual
disease (>2 cm) on completion of initial surgery prior to che-
motherapy. Among the living women, 34 patients (85%)
showed a clinical CR to chemotherapy after surgical treatment
evaluated according to WHO criteria [17], three patients
(7.5%) showed PR, while three patients (7.5%) displayed
disease progression (P) during chemotherapy. None of the
patients had stable disease.
The ages of deceased patients ranged from 30 to 75 years
(mean age was 56.7 years and the average was 57 years). Con-
cerning the grade of differentiation, the series of deceased
women was composed of four cases of G1, 16 cases of G2
Figure 1. CD3 positive tumour-infiltrating T cells were detected in
tumour (A) and in peritumoural stroma (B).
Table 1. Comparison of ovarian cancer patients with disease-free interval
>12 months after primary surgical treatment to patients with brief
disease-free interval (<12 months) (according to logistic regression in
univariate and multivariate analyses)
Variable score Brief disease-free interval
Univariate analysis Multivariate analysis
Odds
ratio
95% CI P Odds
ratio
95% CI P
CD3 positive intratumoural T cells
0
1 0.28 0.1–0.7 0.012 0.21 0.72–0.61 0.004
Residual disease
0
1 1.8 0.77–4.63 0.16 2.1 0.82–5.8 0.11
Grade of differentiation
(G1) 0
(G2) 1 0.28 0.06–1.1 0.085 0.2 0.41–1.02 0.54











and 35 of G3. Concerning the residual disease after surgery,
28 women (50.9%) had absent/minimal residual disease after
surgery (<2 cm) and 27 (49.1%) had bulk residual disease
(>2 cm) on completion of initial surgery prior to chemo-
therapy. Among the deceased women, 28 patients (50.9%)
showed a clinical CR to chemotherapy after surgical treatment
evaluated according to WHO criteria, six patients (10.9%)
showed a PR, while in 21 patients (38.2%) the disease pro-
gressed during chemotherapy (P). None of the patients had
stable disease.
The overall 36 month cause-specific survival rate was
57.8%. The brief disease-free interval rate was 65.2%.
Intratumoural T cells and correlation with
clinico-pathological data
CD3 positive tumour-infiltrating T cells were detected in
tumour and in peritumoural stroma (Figure 1A and B). CD3
positive T cells were counted in 58 cases (89.4%). Among the
Figure 2. (A) Ovarian cancer patients whose tumours contained CD3 positive tumour-infiltrating T cells had an average duration of progression-free
survival of 12 months, while the cancer patients whose tumours did not contain CD3 positive T cells had an average duration of progression-free survival
of 6 months (P = 0.004, according to Wilcoxon Mann–Whitney test). (B) Ovarian cancer patients whose tumours contained CD3 positive tumour-infiltrat-
ing T cells had an average duration of overall survival of 43 months, while the cancer patients whose tumours did not contain CD3 positive T cells had an
average duration of overall survival of 22 months (P = 0.0001, according to Wilcoxon Mann–Whitney test). DFI, disease-free interval.
Table 2. Comparison of ovarian cancer patients living with no evident
disease 3 years after primary surgical treatment with patients who had
died of progression of disease no later than 3 years after primary surgical
treatment (according to logistic regression in univariate and multivariate
analyses)
Variable score Survival
Univariate analysis Multivariate analysis
Odds
ratio
95% CI P Odds
ratio
95% CI P
CD3 positive intratumoural T cells
0
1 0.1 0.03–0.3 0.0001 0.05 0.15–0.19 0.0001
Residual disease
0
1 2.54 1.06–6.08 0.03 4.62 1.56–13.6 0.005
Grade of differentiation
(G1) 0
(G2) 1 0.43 0.1–1.81 0.2 0.21 0.03–1.36 0.1
(G3) 2 0.54 0.22–1.32 0.10 0.44 0.14–1.33 0.1
CI, confidence interval.
Table 3. Presence of CD3 positive intratumoural T cells in relation to
responsiveness to the first line chemotherapy (logistic regression in
univariate and multivariate analyses)
Variable score Responsiveness to first line chemotherapy
Univariate analysis Multivariate analysis
Odds ratio 95% CI P Odds ratio 95% CI P
CD3 positive intratumoural T cells
0
1 3.08 1.29–7.34 0.01 4.66 1.71–12.71 0.003
Residual disease
0
1 0.35 0.14–0.83 0.01 0.24 0.09–0.65 0.005
Grade of differentiation
(G1) 0
(G2) 1 1.72 0.39–7.61 0.4 1.91 0.37–9.85 0.43











positive stained cases, 14 (14.7%) were graded 1+, 28 (29.4%)
were graded 2+ and 16 (16.8%) were graded 3+.
CD3 positive tumour-infiltrating T cells are statistically cor-
related with brief disease-free interval and with the survival of
the patient according to the logistic regression in univariate
analysis (P = 0.012 and P = 0.0001, respectively). Using
multivariate logistic regression analysis CD3 positive tumour-
infiltrating T cells were found to be significant independent
predictors of brief disease-free interval and survival (P = 0.004
and P = 0.0001, respectively) (Tables 1 and 2). In addition,
CD3 positive tumour-infiltrating T cells are significantly
associated with clinical responsiveness to first line chemother-
apy in univariate and multivariate analyses (P = 0.01 and
P = 0.003, respectively) (Table 3). Ovarian cancer patients
whose tumours contained CD3 positive tumour-infiltrating T
cells had a median duration of progression-free survival of 12
months and a median duration of overall survival of 43
months, compared to median duration of progression-free sur-
vival of 6 months and a median duration of overall survival of
22 months in patients without CD3 positive tumour-infiltrating
T cells (P = 0.004 and P = 0.0001, respectively, according to
Wilcoxon Mann–Whitney test; Figure 2A and 2B). In
addition, ovarian carcinoma patients whose tumours contained
CD3 positive tumour-infiltrating T cells had a median age of
61 years (range 33–75 years), compared to median age of 53
years (range 30–72 years) in women without CD3 positive
tumour infiltrating T cells (P = 0.034, according to Wilcoxon
Mann–Whitney test; Figure 3).
Molecular assessment of TCRgamma and TCRbeta
Direct molecular assessment of TCRgamma and TCRbeta was
performed. In 86 cases DNA extraction and subsequent PCR
reaction were successful. None of the analysed samples
revealed a molecular assessment of TCRbeta, while 27 samples
(31.3%) revealed a molecular assessment of TCRgamma
(Figure 4).
Molecular assessment of TCRgamma and correlation
with clinico-pathological data
A molecular assessment of TCRgamma was counted in 27
cases (31.3%). Gamma/delta T cells are statistically correlated
with the brief disease-free interval of the serous advanced
ovarian carcinoma patients according to the logistic regression
in univariate analysis (P = 0.036, Table 4). We did not find
gamma/delta T cells associated with overall survival nor with
clinical responsiveness to first line chemotherapy.
Discussion
To the best of our knowledge, a study designed to determine
the direct molecular assessment of TCRgamma and TCRbeta
of intratumoural T cells in a series of primary advanced
untreated ovarian serous carcinomas has never been per-
formed. We observed with PCR no alpha/beta T cells in
advanced ovarian serous carcinoma, but we detected gamma/
delta T cells in 27 cases (31.3%). In addition, we observed
that the presence of gamma/delta T cells was statistically
correlated with brief disease-free interval of the serous
advanced ovarian carcinoma patients.
In addition, our study confirms that intratumoural T cells
have a prognostic role in advanced serous ovarian carcinoma,
Figure 3. In the cases with CD3 positive tumour-infiltrating T cells, the
average age was 61 years (range 33–75 years), while in the cases without
CD3 positive tumour-infiltrating T cells the average age was 53 years
(range 30–72 years) (P = 0.034, according to the Wilcoxon
Mann–Whitney test).
Figure 4. Ethidium bromide stained polyacrylamide gel of PCR products from ovarian serous carcinomas (lanes 1–6), monoclonal control (lane 7),
polyclonal control (lane 8) and control without DNA (lane 9).
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as previously described by Zhang et al. [4]. The results of the
study showed that CD3 positive tumour-infiltrating T cells
detected in tumour and in peritumoural stroma, were statisti-
cally strongly correlated both with brief disease-free interval
and with survival in logistic regression analysis in univariate
and multivariate analyses. In addition, we observed an associ-
ation between the CD3 positive tumour-infiltrating T cells
with clinical responsiveness to first line chemotherapy.
The characterization of tumour-specific antigens has shown
that tumours may have antigen determinants which are recog-
nised by the immune system. A recent study indicated that
these antigens may be tumour-specific peptides that are absent
in all adult normal tissue except germline cells [22]. Immu-
notherapy using adoptive cell transfer is a promising approach
that can result in the regression of bulk, invasive cancer in
some patients [23, 24].
Concerning ovarian cancer, there is reported experimental
evidence that some ovarian carcinoma specimens show a leu-
kocyte infiltrate [4]. In addition, tumour-associated lympho-
cytes with polyclonal expansion were demonstrated in ovarian
cancer cell lines [25, 26]. In ovarian carcinoma patients, it
seems that the clinical outcome may depend on tumour
characteristics (FIGO stage of disease, residual disease, histo-
logic type and grade of differentiation) and on host response
to cancer. The manipulation of immune mechanisms may
offer powerful therapeutic tools for treatment of ovarian carci-
noma patients. In recent years, several studies have focused
on the possible use of T cells to attack established tumours.
Lamers et al. [27] showed a local, but non systemic immuno-
modulation by intraperitoneal treatment of advanced ovarian
carcinoma with autologous T cells. In the years to come, the
knowledge of new data regarding T cells, such as the receptor
pathway [28, 29] may give further data for the immunomodu-
lation of therapeutic treatment in ovarian carcinoma patients.
In this study, we observed a brief disease-free interval in
81.4% of the cases showing gamma/delta T cells, while the
brief disease-free interval rate is 57.6% in cases showing no
gamma/delta T cells (P = 0.036). Moreover, a recent study
[30] showed that gamma/delta T cells, involved in inflamma-
tory responses, play a central role in tissue damage.
Further studies are required to better understand the nega-
tive prognostic role of gamma/delta T cells in ovarian carci-
noma, yet these data underline the importance of immune host
response to cancer and the need to better study the immune
mechanisms to modulate the therapeutic treatment of cancer.
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